Close
ACHEMA MIDDLE EAST 2026

Drug Nod Delays Not Hampering South Korean Pharma Position

According to a survey from Fitch Solutions, South Korea's pharmaceutical market attractiveness is expected to stay strong despite ongoing concerns about the country's slow...

Medicine Patient Pool For 2023-25 To Curb Drug Inequalities

A novel strategy for 2023–25 adopted by the Medicines Patent Pool looks to lessen the inequalities in access by way of enhancing the affordability...

Acute Leukaemia May Find Saviour In PIK-75, An Existing Drug

National University of Singapore researchers have gone ahead and revisited a drug which they believe can be a problem solver when it comes to...

FDA Comes With A Research Map Concerning Biosimilars Program

The FDA has gone on to release the Biosimilar User Fee Amendments III Regulatory Science Pilot Program, called the Research Roadmap, to give out...

Getting Immunotherapy Work In Case of Pancreatic Cancer

One of the latest studies that takes into account the tumour microenvironment of pancreatic cancer puts forth the cause that tumour cells are resistant...

Monoclonal Antibodies Ideal Against Malaria- Suggests Study

Only one dose of the monoclonal antibody (mAb) CIS43LS gave out high levels of protection against Malaria in challenge study as per new research....

A New UK Manufacturing Regulatory Framework On The Cards

As UK will introduce a customised framework for the innovative medicines’ regulation manufactured at the point where the care is received by the patient,...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...